Published in Genes Dev on April 15, 2012
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene (2012) 2.41
Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U S A (2013) 2.25
Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci Transl Med (2013) 1.99
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev (2013) 1.55
Adult Lineage-Restricted CNS Progenitors Specify Distinct Glioblastoma Subtypes. Cancer Cell (2015) 1.49
IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res (2012) 1.36
A 16-gene signature distinguishes anaplastic astrocytoma from glioblastoma. PLoS One (2014) 1.26
Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res (2015) 1.22
mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci U S A (2013) 1.20
Exomic sequencing of four rare central nervous system tumor types. Oncotarget (2013) 1.17
Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer (2015) 1.15
Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma. Clin Cancer Res (2013) 1.13
miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes Dev (2015) 1.08
EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties. Oncogene (2014) 1.08
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov (2013) 1.07
Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res (2013) 1.07
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol (2014) 1.06
Functional imaging in adult and paediatric brain tumours. Nat Rev Clin Oncol (2012) 1.05
NF-κB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma. PLoS One (2013) 1.04
Role of SOX family of transcription factors in central nervous system tumors. Am J Cancer Res (2014) 1.01
EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180. Oncogene (2013) 1.00
Tumor metabolism of malignant gliomas. Cancers (Basel) (2013) 1.00
Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. Cancer Res (2014) 0.98
Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma. Med Phys (2015) 0.97
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest (2014) 0.97
Ionizing radiation in glioblastoma initiating cells. Front Oncol (2013) 0.95
Altered expression of polycomb group genes in glioblastoma multiforme. PLoS One (2013) 0.95
Modeling Tumor-Associated Edema in Gliomas during Anti-Angiogenic Therapy and Its Impact on Imageable Tumor. Front Oncol (2013) 0.95
Notching on Cancer's Door: Notch Signaling in Brain Tumors. Front Oncol (2015) 0.95
Isoform-level gene signature improves prognostic stratification and accurately classifies glioblastoma subtypes. Nucleic Acids Res (2014) 0.94
Conditional astroglial Rictor overexpression induces malignant glioma in mice. PLoS One (2012) 0.93
Cytokine patterns in brain tumour progression. Mediators Inflamm (2013) 0.92
MiR-181b sensitizes glioma cells to teniposide by targeting MDM2. BMC Cancer (2014) 0.91
Epidermal growth factor receptor targeting and challenges in glioblastoma. Neuro Oncol (2016) 0.91
Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma. Stem Cells (2014) 0.91
Current status of gene therapy for brain tumors. Transl Res (2012) 0.90
A glioma classification scheme based on coexpression modules of EGFR and PDGFRA. Proc Natl Acad Sci U S A (2014) 0.90
Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates. Acta Neuropathol (2013) 0.90
Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biol Med (2013) 0.89
The vacuolar H+ ATPase is a novel therapeutic target for glioblastoma. Oncotarget (2015) 0.89
Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors. CNS Oncol (2013) 0.88
Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma. PLoS One (2013) 0.88
OSU-03012 interacts with lapatinib to kill brain cancer cells. Cancer Biol Ther (2012) 0.88
USP11 regulates PML stability to control Notch-induced malignancy in brain tumours. Nat Commun (2014) 0.88
Strategies in gene therapy for glioblastoma. Cancers (Basel) (2013) 0.87
Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy. Stem Cells (2014) 0.87
Collateral Lethality: A new therapeutic strategy in oncology. Trends Cancer (2015) 0.87
Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition. Mol Cancer Ther (2015) 0.86
Glioma cell proliferation controlled by ERK activity-dependent surface expression of PDGFRA. PLoS One (2014) 0.86
Aptamer identification of brain tumor-initiating cells. Cancer Res (2013) 0.86
A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Res (2014) 0.85
Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome. Sci Rep (2016) 0.84
KDM1 is a novel therapeutic target for the treatment of gliomas. Oncotarget (2013) 0.84
Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity. Dis Model Mech (2015) 0.83
Gene therapy for malignant glioma. Mol Cell Ther (2014) 0.83
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Cell Cycle (2015) 0.83
Development of targeted therapies in treatment of glioblastoma. Cancer Biol Med (2015) 0.83
Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness. J Biol Chem (2015) 0.82
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms. Cancer Res (2015) 0.82
CD151-α3β1 integrin complexes are prognostic markers of glioblastoma and cooperate with EGFR to drive tumor cell motility and invasion. Oncotarget (2015) 0.82
Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. J Neurosci (2015) 0.81
Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants. World J Clin Oncol (2014) 0.81
Contemporary murine models in preclinical astrocytoma drug development. Neuro Oncol (2014) 0.81
Plexin-B2 promotes invasive growth of malignant glioma. Oncotarget (2015) 0.81
Integrative genetic, epigenetic and pathological analysis of paraganglioma reveals complex dysregulation of NOTCH signaling. Acta Neuropathol (2013) 0.81
Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. J Neurooncol (2014) 0.81
The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. Cancer Lett (2016) 0.81
PRG3 induces Ras-dependent oncogenic cooperation in gliomas. Oncotarget (2016) 0.80
Identifying glioblastoma gene networks based on hypergeometric test analysis. PLoS One (2014) 0.80
Response to imatinib as a function of target kinase expression in recurrent glioblastoma. Springerplus (2014) 0.80
Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. J Neurochem (2015) 0.80
Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells. Oncotarget (2015) 0.80
Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours. Br J Cancer (2014) 0.80
Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H. Neurotherapeutics (2014) 0.80
Activation of protease-activated receptor 2 reduces glioblastoma cell apoptosis. J Biomed Sci (2014) 0.80
The impact of dietary isoflavonoids on malignant brain tumors. Cancer Med (2014) 0.79
Evidence for post-translational processing of vascular endothelial (VE)-cadherin in brain tumors: towards a candidate biomarker. PLoS One (2013) 0.79
Survivin transcript variant 2 drives angiogenesis and malignant progression in proneural gliomas. Neuro Oncol (2014) 0.79
Medical therapy of gliomas. J Neurooncol (2014) 0.79
Computational Identification of Tumor Anatomic Location Associated with Survival in 2 Large Cohorts of Human Primary Glioblastomas. AJNR Am J Neuroradiol (2016) 0.79
Better prognosis of patients with glioma expressing FGF2-dependent PDGFRA irrespective of morphological diagnosis. PLoS One (2013) 0.78
ROS1 amplification mediates resistance to gefitinib in glioblastoma cells. Oncotarget (2015) 0.78
Cell-SELEX aptamer for highly specific radionuclide molecular imaging of glioblastoma in vivo. PLoS One (2014) 0.78
Id2 mediates oligodendrocyte precursor cell maturation arrest and is tumorigenic in a PDGF-rich microenvironment. Cancer Res (2014) 0.78
Glial progenitors as targets for transformation in glioma. Adv Cancer Res (2014) 0.78
Silencing of protein kinase D2 induces glioma cell senescence via p53-dependent and -independent pathways. Neuro Oncol (2014) 0.78
Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy. Stem Cells Int (2016) 0.78
Down-regulation of HSP60 Suppresses the Proliferation of Glioblastoma Cells via the ROS/AMPK/mTOR Pathway. Sci Rep (2016) 0.78
Deregulated expression of TANK in glioblastomas triggers pro-tumorigenic ERK1/2 and AKT signaling pathways. Oncogenesis (2013) 0.78
New perspectives in glioblastoma antiangiogenic therapy. Contemp Oncol (Pozn) (2015) 0.78
MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis. Oncogene (2016) 0.78
Elucidation of the genetic and epigenetic landscape alterations in RNA binding proteins in glioblastoma. Oncotarget (2016) 0.78
Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nat Genet (2016) 0.78
Expressions of glia maturation factor-β by tumor cells and endothelia correlate with neovascularization and poor prognosis in human glioma. Oncotarget (2016) 0.77
Asymmetric Distribution of GFAP in Glioma Multipotent Cells. PLoS One (2016) 0.77
Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres. Mol Cancer (2013) 0.77
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
The cancer genome. Nature (2009) 23.13
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 18.26
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
Reverse engineering of regulatory networks in human B cells. Nat Genet (2005) 13.16
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Tumorigenesis and the angiogenic switch. Nat Rev Cancer (2003) 11.95
A perivascular niche for brain tumor stem cells. Cancer Cell (2007) 11.55
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
Tumor angiogenesis. N Engl J Med (2008) 11.30
Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2010) 11.16
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science (2009) 10.78
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A (2003) 10.56
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2004) 10.55
Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (1994) 10.34
Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15
PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 9.94
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol (2008) 8.79
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
The transcriptional network for mesenchymal transformation of brain tumours. Nature (2009) 8.44
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology (2008) 8.10
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature (2011) 7.94
Gene expression profiling of gliomas strongly predicts survival. Cancer Res (2004) 7.79
Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol (2008) 7.79
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (2009) 7.73
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther (2007) 7.08
Cells of origin in cancer. Nature (2011) 6.85
Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell (2009) 6.77
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res (2008) 6.44
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 6.43
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol (2005) 6.16
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006) 6.15
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature (2010) 6.13
Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia (2002) 5.81
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol (2011) 5.73
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med (2010) 5.68
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science (1998) 5.62
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov (2011) 5.59
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51
Mosaic analysis with double markers in mice. Cell (2005) 5.32
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst (1998) 5.30
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One (2009) 5.08
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol (2009) 5.06
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res (2007) 4.99
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell (2009) 4.94
Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med (2011) 4.91
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep (2011) 4.89
Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell (2009) 4.82
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
International network of cancer genome projects. Nature (2010) 20.35
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
A landscape of driver mutations in melanoma. Cell (2012) 12.61
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
p16INK4a induces an age-dependent decline in islet regenerative potential. Nature (2006) 9.09
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Highly recurrent TERT promoter mutations in human melanoma. Science (2013) 8.40
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2006) 8.26
PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell (2005) 8.22
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A (2003) 7.30
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A (2005) 6.52
Telomere dysfunction induces metabolic and mitochondrial compromise. Nature (2011) 6.36
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
A genetic screen for candidate tumor suppressors identifies REST. Cell (2005) 5.61
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov (2006) 5.11
Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature (2010) 5.02
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
A public genome-scale lentiviral expression library of human ORFs. Nat Methods (2011) 4.98
Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet (2002) 4.76
Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab (2007) 4.74
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68